Melanoma Clinical Trials in Chicago

Showing 201-220 of 284 trials

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

NCT01227551

The purpose of this study is to assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months as monitored via immune-related Response Criteria \[irRECIST 1.1\] (revised Response Evaluation Criteria In Solid Tumors \[RECIST\] 1.1).

Malignant Melanoma

Viralytics57 participantsStarted Dec 2011

La Jolla, California, United States • San Francisco, California, United States • Miami Beach, Florida, United States +7 more locations

COMPLETED2.2 miles

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

NCT01415167

The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.

Metastatic Renal Cell CarcinomaMetastatic Melanoma

Prometheus Laboratories1,690 participantsStarted Aug 2011

Tucson, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +42 more locations

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Melanoma Trials in Other Cities

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using Mobile App Technology

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Promoting Early Detection of Melanoma During the Mammography Experience

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

A Study of Vemurafenib in Participants With Metastatic Melanoma

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Other Conditions in Chicago